Bioenvision Appoints James S. Scibetta as New CFO
November 28 2006 - 7:00AM
Business Wire
Bioenvision, Inc. (NasdaqGM:BIVN) today announced the appointment
James S. Scibetta to the post of Chief Financial Officer. Mr.
Scibetta will begin his employment with Bioenvision in early
December 2006. Mr. Scibetta, with 18 years of experience as a
finance professional, will become the Company�s new CFO. Mr.
Scibetta was most recently Executive Vice President & CFO of
Merrimack Pharmaceuticals, Inc. of Cambridge, Massachusetts, a
biopharmaceutical company focused on discovery and development of
novel therapies for autoimmune disease and cancer. Mr. Scibetta is
a member of the board of directors and audit committee chairman of
Labopharm Inc. (Nasdaq:DDSS, TSX:DDS), an international, specialty
pharmaceutical company focused on improving existing drugs by
incorporating its proprietary, advanced controlled-release
technologies, and formerly has served as a senior investment banker
providing capital raising, M&A and strategic advisory services
to healthcare companies at Shattuck Hammond Partners, LLC, a
boutique healthcare investment bank and PaineWebber Inc. �We are
very pleased to have someone with Jim�s experience joining the
Bioenvision team,� said Dr. Christopher Wood, Bioenvision�s
Chairman and CEO. Mr. Scibetta said. �I look forward to working
with the current management team and using my skills and experience
to help Bioenvision manage through the coming stages of growth and
opportunity.� David P. Luci, formerly Bioenvision�s Chief Financial
Officer, General Counsel and Corporate Secretary, will be promoted
to the position of Executive Vice President, General Counsel and
Corporate Secretary, focusing on business and product development
activities and continuing to manage the Company�s legal and
regulatory matters. About Bioenvision Bioenvision�s primary focus
is the acquisition, development, distribution and marketing of
compounds and technologies for the treatment of cancer. Bioenvision
has a broad pipeline of products for the treatment of cancer,
including: Evoltra�, Modrenal� (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products. Bioenvision is also
developing anti-infective technologies, including the OLIGON�
technology, an advanced biomaterial that has been incorporated into
various FDA approved medical devices and Suvus�, an antimicrobial
agent currently in clinical development for refractory chronic
hepatitis C infection. For more information on Bioenvision please
visit our Web site at www.bioenvision.com. Certain statements
contained herein are �forward-looking� statements (as such term is
defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. Specifically, factors that could
cause actual results to differ materially from those expressed or
implied by such forward-looking statements include, but are not
limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the
potential failure of Bioenvision's compounds under development to
prove safe and effective for treatment of disease; uncertainties
inherent in the early stage of Bioenvision's compounds under
development; failure to successfully implement or complete clinical
trials; failure to receive marketing clearance from regulatory
agencies for our compounds under development; acquisitions,
divestitures, mergers, licenses or strategic initiatives that
change Bioenvision's business, structure or projections; the
development of competing products; uncertainties related to
Bioenvision's dependence on third parties and partners; and those
risks described in Bioenvision's filings with the SEC. Bioenvision
disclaims any obligation to update these forward-looking
statements. Bioenvision, Inc. (NasdaqGM:BIVN) today announced the
appointment James S. Scibetta to the post of Chief Financial
Officer. Mr. Scibetta will begin his employment with Bioenvision in
early December 2006. Mr. Scibetta, with 18 years of experience as a
finance professional, will become the Company's new CFO. Mr.
Scibetta was most recently Executive Vice President & CFO of
Merrimack Pharmaceuticals, Inc. of Cambridge, Massachusetts, a
biopharmaceutical company focused on discovery and development of
novel therapies for autoimmune disease and cancer. Mr. Scibetta is
a member of the board of directors and audit committee chairman of
Labopharm Inc. (Nasdaq:DDSS, TSX:DDS), an international, specialty
pharmaceutical company focused on improving existing drugs by
incorporating its proprietary, advanced controlled-release
technologies, and formerly has served as a senior investment banker
providing capital raising, M&A and strategic advisory services
to healthcare companies at Shattuck Hammond Partners, LLC, a
boutique healthcare investment bank and PaineWebber Inc. "We are
very pleased to have someone with Jim's experience joining the
Bioenvision team," said Dr. Christopher Wood, Bioenvision's
Chairman and CEO. Mr. Scibetta said. "I look forward to working
with the current management team and using my skills and experience
to help Bioenvision manage through the coming stages of growth and
opportunity." David P. Luci, formerly Bioenvision's Chief Financial
Officer, General Counsel and Corporate Secretary, will be promoted
to the position of Executive Vice President, General Counsel and
Corporate Secretary, focusing on business and product development
activities and continuing to manage the Company's legal and
regulatory matters. About Bioenvision Bioenvision's primary focus
is the acquisition, development, distribution and marketing of
compounds and technologies for the treatment of cancer. Bioenvision
has a broad pipeline of products for the treatment of cancer,
including: Evoltra(R), Modrenal(R) (for which Bioenvision has
obtained regulatory approval for marketing in the United Kingdom
for the treatment of post-menopausal breast cancer following
relapse to initial hormone therapy), and other products.
Bioenvision is also developing anti-infective technologies,
including the OLIGON(R) technology, an advanced biomaterial that
has been incorporated into various FDA approved medical devices and
Suvus(R), an antimicrobial agent currently in clinical development
for refractory chronic hepatitis C infection. For more information
on Bioenvision please visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to: risks associated with
preclinical and clinical developments in the biopharmaceutical
industry in general and in Bioenvision's compounds under
development in particular; the potential failure of Bioenvision's
compounds under development to prove safe and effective for
treatment of disease; uncertainties inherent in the early stage of
Bioenvision's compounds under development; failure to successfully
implement or complete clinical trials; failure to receive marketing
clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure
or projections; the development of competing products;
uncertainties related to Bioenvision's dependence on third parties
and partners; and those risks described in Bioenvision's filings
with the SEC. Bioenvision disclaims any obligation to update these
forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From May 2024 to Jun 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2023 to Jun 2024